Eris Lifesciences is using its growing insulin business to position itself as a serious contender in India’s fast-expanding ...

Russia is currently experiencing a boom in the sales of Ozempic (semaglutide) and its analogues due to a high demand for such drugs among domestic customers, reports The Pharma Letter’s local ...

Novo Nordisk stock was downgraded to Neutral from Buy by UBS analysts, who cited the threat posed by its U.S. rival.

This potential loss of strength when taking Ozempic could be a particular concern for adults over the age of 60 who are at a ...

President Donald Trump says pharma tariffs could go as high as 250%. UBS downgrades Novo Nordisk stock to neutral and lowers ...

The telehealth company posted revenue of $544.8 million in the second quarter, marking a 73% increase year over year but missing analyst estimates for $552 million, according to Bloomberg data. Hims & ...

Novo Nordisk A/V (NYSE: NVO) stock is testing the patience of buy-and-hold investors. Over the last five years, NVO stock is ...

At least 26 patients have filed lawsuits in Marion County against Eli Lilly and Co. over its marketing of GLP-1 drugs ...

Novo Nordisk underestimated the impact of competition from personalized compounded drugs when providing sales estimates for ...

Novo Nordisk is scheduled to report results for the second quarter on Wednesday. Here is what you need to know: PROFIT FORECAST: The company pre-released preliminary second-quarter numbers last week, ...

Vivani reported Phase 1 success for its exenatide implant and shared preclinical semaglutide data showing 231-day weight loss ...

Hims & Hers Health Inc. (NYSE: HIMS) plunged 13.1% in Tuesday pre-market after the digital health company reported ...